<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2610222809
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZINOPRIL 10 MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LISINOPRIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        26.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09AA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zinopril contains a medicine called lisinopril. This belongs to a group of medicines called ACE inhibitors.<br />Zinopril can be used for the following conditions:</p><ul><li>To treat high blood pressure (hypertension).</li><li>To treat heart failure.</li><li>If you have recently had a heart attack (myocardial infarction).</li><li>To treat kidney problems caused by Type II diabetes in people with high blood pressure.</li></ul><p>Zinopril works by making your blood vessels widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood to all parts of your body.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Zinopril:</strong></p><ul><li>If you are allergic to lisinopril or any of the other ingredients of this medicine (listed in section 6).</li><li>If you have ever had an allergic reaction to another ACE inhibitor medicine. The allergic reaction may have caused swelling of the hands, feet, ankles, face, lips, tongue or throat. It may also have made it difficult to swallow or breathe (angioedema).</li><li>If a member of your family has had severe allergic reactions (angioedema) to an ACE inhibitor or you have had severe allergic reactions (angioedema) without a known cause.</li><li>If you are more than 3 months pregnant. (It is also better to avoid Zinopril in early pregnancy - see Pregnancy section).</li><li>&nbsp;If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren. If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking Zinopril.</li></ul><p>If you develop a dry cough which is persistent for a long time after starting treatment with Zinopril, talk to your doctor.&nbsp;</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Zinopril:</p><ul><li>If you have a narrowing (stenosis) of the aorta (an artery in your heart) or a narrowing of the heart valves (mitral valves).</li><li>If you have a narrowing (stenosis) of the kidney artery.</li><li>If you have an increase in the thickness of the heart muscle (known as hypertrophic cardiomyopathy).</li><li>If you have problems with your blood vessels (collagen vascular disease).</li><li>If you have low blood pressure. You may notice this as feeling dizzy or light-headed, especially when standing up.</li><li>If you have kidney problems or you are having kidney dialysis.</li><li>If you have liver problems.</li><li>If you have diabetes.</li><li>If you are taking any of the following medicines used to treat high blood pressure:</li></ul><p>o An angiotensin II receptor blocker (arbs) (also known as sartans &ndash; for example valsartan, telmisartan, irbesartan), in particular if you have diabetes related kidney problems</p><p>o Aliskiren.</p><p>Your doctor may check your kidney function, blood pressure and the amount of electrolytes (e.g. potassium) in your blood at regular intervals. See also information under the heading &ldquo;Do not take Zinopril&rdquo;.</p><ul><li>&nbsp;If you have recently had diarrhoea or vomiting (being sick).</li><li>&nbsp;If your doctor has told you to control the amount of salt in your diet.</li><li>&nbsp;If you have high levels of cholesterol and you are having a treatment called &lsquo;ldl apheresis&rsquo;.</li><li>&nbsp;You must tell your doctor if you think you are (or might become) pregnant. Zinopril is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</li><li>&nbsp;If you are of black origin as zinopril may be less effective. You may also more readily get the side effect &lsquo;angioedema&rsquo; (a severe allergic reaction).</li></ul><p>If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking Zinopril.</p><p><strong>Treatment for allergies such as insect stings</strong><br />Tell your doctor if you are having or are going to have treatment to lower the effects of an allergy such as insect stings (desensitisation treatment). If you take Zinopril while you are having this treatment, it may cause a severe allergic reaction.<br /><strong>Operations</strong></p><p>If you are going to have an operation (including dental surgery) tell your doctor or dentist that you are taking Zinopril. This is because you can get low blood pressure (hypotension) if you are given certain local or general anaesthetics while you are taking Zinopril.<br /><strong>Children and adolescents</strong><br />Zinopril has been studied in children. For more information, talk to your doctor. Zinopril is not recommended in children under 6 years of age or in any child with severe kidney problems.<br /><strong>Other medicines and Zinopril</strong><br />Tell your doctor if you are taking, or have recently taken, or might take any other medicines. This is because Zinopril can affect the way some medicines work and some medicines can have an effect on Zinopril. Your doctor may need to change your dose and/or to take other precautions.<br />In particular, tell your doctor or pharmacist if you are taking any of the following medicines:</p><ul><li>Other medicines to help lower your blood pressure.</li><li>An angiotensin II receptor blocker (ARB) or aliskiren, (see also information under the headings &ldquo;Do not take Zinopril&rdquo; and &ldquo;Warnings and precautions&rdquo;).</li><li>Water tablets (diuretic medicines).</li><li>Medicines to break up blood clots (usually given in hospital).</li><li>Beta-blocker medicines, such as atenolol and propranolol.</li><li>Nitrate medicines (for heart problems).</li><li>Non-steroidal anti-inflammatory drugs (NSAIDs) used to treat pain and arthritis.</li><li>Aspirin (Acetylsalicylic acid), if you are taking more than 3 grams each day.</li><li>Medicines for depression and for mental problems, including lithium.</li><li>Potassium tablets or salt substitutes that have potassium in them.</li><li>Insulin or medicines that you take by mouth for diabetes.</li><li>Medicines used to treat asthma.</li><li>Medicines to treat nose or sinus congestion or other cold remedies (including those you can buy in the pharmacy).</li><li>Medicines to suppress the body&rsquo;s immune response (immunosuppressants).</li><li>Allopurinol (for gout).</li><li>Procainamide (for heart beat problems).</li><li>Medicines that contain gold, such as sodium aurothiomalate, which may be given to you as an injection.</li></ul><p><strong>Pregnancy and breast-feeding</strong><br /><strong>Pregnancy:</strong><br />You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Zinopril before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Zinopril. Zinopril is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.<br /><strong>Breast-feeding:</strong><br />Tell your doctor if you are breast-feeding or about to start breast-feeding. Zinopril is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.<br /><strong>Driving and using machines</strong></p><ul><li>Some people feel dizzy or tired when taking this medicine. If this happens to you, do not drive or use any tools or machines.</li><li>You must wait to see how your medicine affects you before trying these activities.</li><li>How to take Zinopril</li></ul><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br />Once you have started taking Zinopril your doctor may take blood tests. Your doctor may then adjust your dose so you take the right amount of medicine for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Swallow the tablet with a drink of water.</li><li>Try to take your tablets at the same time each day. It does not matter if you take Zinopril before or after food.</li><li>Keep taking Zinopril for as long as your doctor tells you to, it is a long term treatment. It is important to keep taking Zinopril every day.</li></ul><p><strong>Taking your first dose</strong></p><ul><li>Take special care when you have your first dose of Zinopril or if your dose is increased. It may cause a greater fall in blood pressure than later doses.</li><li>This may make you feel dizzy or light-headed. If this happens, it may help to lie down. If you are concerned, please talk to your doctor as soon as possible.</li></ul><p><strong>Adults</strong></p><p>Your dose depends on your medical condition and whether you are taking any other medicines. Your doctor will tell you how many tablets to take each day. Check with your doctor or pharmacist if you are unsure.</p><p><strong>For high blood pressure</strong></p><ul><li>The recommended starting dose is 10 mg once a day.</li><li>The usual long-term dose is 20 mg once a day.</li></ul><p><strong>For heart failure</strong></p><ul><li>The recommended starting dose is 2.5 mg once a day.</li><li>The long-term dose is 5 to 35 mg once a day.</li></ul><p><strong>After a heart attack</strong></p><ul><li>The recommended starting dose is 5 mg within 24 hours of your attack and 5 mg one day later.</li><li>The usual long-term dose is 10 mg once a day.</li></ul><p><strong>For kidney problems caused by diabetes</strong></p><ul><li>The recommended dose is either 10 mg or 20 mg once a day.</li></ul><p>If you are elderly, have kidney problems or are taking diuretic medicines your doctor may give you a lower dose than the usual dose.</p><p><strong>Use in children and adolescents (6 to 16 years old) with high blood pressure</strong></p><ul><li>Zinopril is not recommended for children under 6 years or in any children with severe kidney problems.</li><li>The doctor will work out the correct dose for your child. The dose depends on the child&rsquo;s body weight.</li><li>For children who weigh between 20 kg and 50 kg, the recommended starting dose is 2.5 mg once a day.</li><li>For children who weigh more than 50 kg, the recommended starting dose is 5 mg once a day.</li></ul><p><strong>If you take more Zinopril than you should</strong></p><p>If you take more Zinopril than prescribed by your doctor, talk to a doctor or go to a hospital immediately. The following effects are most likely to happen: Dizziness, palpitations.</p><p><strong>If you forget to take Zinopril</strong></p><ul><li>If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose.</li><li>Do not take a double dose to make up for a forgotten dose.</li></ul><p><strong>If you stop taking Zinopril</strong><br />Do not stop taking your tablets, even if you are feeling well, unless your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If you experience any of the following reactions, <strong>stop taking Zinopril and see your doctor immediately:</strong></p><ul><li>Severe allergic reactions (rare, affects 1 to 10 users in 10,000). The signs may include sudden onset of:</li></ul><p>- Swelling of your face, lips, tongue or throat. This may make it difficult to swallow.</p><p>- Severe or sudden swelling of your hands, feet and ankles.</p><p>- Difficulty breathing.</p><p>- Severe itching of the skin (with raised lumps).</p><ul><li>Severe skin disorders, like a sudden, unexpected rash or burning, red or peeling skin (very rare, affects less than 1 user in 10,000).</li><li>An infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems (very rare, affects less than 1 user in 10,000).</li></ul><p><strong>Other possible side effects:</strong><br /><strong>Common (affects 1 to 10 users in 100)</strong></p><ul><li>Headache.</li><li>Feeling dizzy or light-headed, especially if you stand up quickly.</li><li>Diarrhoea.</li><li>A dry cough that does not go away.</li><li>Being sick (vomiting).</li><li>Kidney problems (shown in a blood test).</li></ul><p><strong>Uncommon (affects 1 to 10 users in 1,000)</strong></p><ul><li>Mood changes.</li><li>Change of colour in your fingers or toes (pale blue followed by redness) or numbness or tingling in your fingers or toes.</li><li>Changes in the way things taste.</li><li>Feeling sleepy.</li><li>Spinning feeling (vertigo).</li><li>Having difficulty sleeping.</li><li>Stroke.</li><li>Fast heartbeat.</li><li>Runny nose.</li><li>Feeling sick (nausea).</li><li>Stomach pain or indigestion.</li><li>Skin rash or itching.</li><li>Being unable to get an erection (impotence).</li><li>Feeling tired or feeling weak (loss of strength).</li><li>A very big drop in blood pressure may happen in people with the following conditions:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; coronary heart disease; narrowing of the aorta (a heart artery), kidney artery or heart valves; an increase in the thickness of the heart muscle. If this happens to you, you may feel dizzy or light-headed, especially if you stand up quickly.</li><li>Changes in blood tests that show how well your liver and kidneys are working.</li><li>Heart attack.</li><li>Seen and/or heard hallucinations.</li></ul><p><strong>Rare (affects 1 to 10 users in 10,000)</strong></p><ul><li>Feeling confused.</li><li>A lumpy rash (hives).</li><li>Dry mouth.</li><li>Hair loss.</li><li>Psoriasis (a skin problem).</li><li>Changes in the way things smell.</li><li>Development of breasts in men.</li><li>Changes to some of the cells or other parts of your blood. Your doctor may take blood samples from time to time to check whether Zinopril has had any effect on your blood. The signs may include feeling tired, pale skin, a sore throat, high temperature (fever), joint and muscle pains, swelling of the joints or glands, or sensitivity to sunlight.</li><li>Low levels of sodium in your blood (the symptoms may be tiredness, headache, nausea, vomiting).</li><li>Sudden renal failure.</li></ul><p><strong>Very rare (affect less than 1 user in 10,000)</strong></p><ul><li>Sinusitis (a feeling of pain and fullness behind your cheeks and eyes).</li><li>Wheezing.</li><li>Low levels of sugar in your blood (hypoglycaemia). The signs may include feeling hungry or weak, sweating and a fast heartbeat.</li><li>Inflammation of the lungs. The signs include cough, feeling short of breath and high temperature (fever).</li><li>Yellowing of the skin or the whites of the eyes (jaundice).</li><li>Inflammation of the liver. This can cause loss of appetite, yellowing of the skin and eyes, and dark coloured urine.</li><li>Inflammation of the pancreas. This causes moderate to severe pain in the stomach.</li><li>Severe skin disorders. The symptoms include redness, blistering and peeling.</li><li>Sweating.</li><li>Passing less water (urine) than normal or passing no water.</li><li>Liver failure.</li><li>Lumps.</li><li>Inflamed gut.</li></ul><p><strong>Not known (frequency cannot be estimated from available data)</strong></p><ul><li>Symptoms of depression.</li><li>Fainting.</li></ul><p>Side effects in children appear to be comparable to those seen in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep this medicine out of the sight and reach of children.</li><li>Do not use this medicine after the expiry date (EXP) which is stated on the blister strip and the carton. The expiry date refers to the last day of that month.</li><li>5 mg, 10 mg and 20 mg tablets: Do not store above 30&ordm;C.</li><li>Do not throw away any medicines via waste-water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is lisinopril (as dihydrate).</li><li>The other ingredients are Microcrystalline Cellulose; Sodium Starch Glycolate (Primojel); Colloidal Anhydrous Silica (Aerosil 200); Magnesium Stearate and Red iron oxide( for 10 mg and 20 mg).</li></ul><p>Zinopril is supplied in 3 strengths containing 5 mg, 10 mg or 20 mg of lisinopril (as dihydrate).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zinopril 5 mg tablets are white to off-whit scored round biconvex embossed with “JI” on the upper scored part and “45” on the lower scored part.
Zinopril 10 mg tablets are Pinkish-Orange scored round embossed with “JI” on the upper scored part and “42” on the lower scored part.
Zinopril 20 mg tablets are Brick red scored round embossed with “JI” on the upper scored part and “43” on the lower scored part.

Zinopril tablets are available in aluminium foil blister packs of 28 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jazeera Pharmaceutical Industries (JPI)</p><p>Riyadh, Saudi Arabia, 11666 Riyadh, P.O.Box 106229</p><p>Phone No.: +966-11-207-8172</p><p>Fax: +966-11-207-8097</p><p>E-mail: <u>medical@jpi.com.sa</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2016, version 1.1
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>زينوبريل يحتوي على المادة الفعالة لسينوبريل، ينتمي إلى مجموعة دوائية تسمى مثبطات الأنجيوتنسن يمكن يستخدم زينوبريل للحالات التالية :</p><ul><li dir="rtl">معالجة ارتفاع ضغط الدم.</li><li dir="rtl">&nbsp;معالجة الفشل القلبي.</li><li dir="rtl">&nbsp;إذا اصبت مؤخرا بنوبة قلبية (احتشاء عضلة القلب).</li><li dir="rtl">&nbsp;معالجة مشاكل الكلى الناتجة من مرض السكري النوع الثاني مع ارتفاع بضغط الدم.</li></ul><p>يعمل زينوبريل على توسعة أوعية القلب، مما يساعد ذلك على انخفاض ضغط الدم. مما يسهل ضخ الدم من القلب الى الأجزاء الأخرى من الجسم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع استعمال زينوبريل:</strong></p><ul><li dir="rtl">&nbsp;اذا كنت مصاب بحساسية تجاه لسينوبريل أو أي من المكونات الأخرى لهذا دواء (المدرجة في قسم 6).</li><li dir="rtl">&nbsp;اذا كانت لديك حساسية تجاه اي دواء اخر يعمل على تثبيط الأنجيوتنسن. رد الفعل التحسسي هذا يسبب تورم اليدين، القدمين، الكاحلين، الوجه، الشفاه، اللسان أو الحلق. قد يسبب ذلك ايضا صعوبة في البلع او التنفس (وذمة وعائية).</li><li dir="rtl">اذا كان اي فرد من العائلة لديه ردود الفعل التحسسية (وذمة وعائية)&nbsp;للأدوية المثبطة للأنجيوتنسن، أو كانت لديك رد فعل تحسسي خطير (الوذمة الوعائية) من سبب غير معروف.</li><li dir="rtl">&nbsp;اذا كنتي حاملا لأكثر من ثلاثة اشهر .(من الأفضل تجنب تناول زينوبريل حتى في مرحلة مبكرة من فترة الحمل &ndash; اطلع على قسم الحمل والرضاعة).</li><li dir="rtl">&nbsp;إذا كنت مصاب بمرض السكري أو اختلال وظائف الكلى وتتم معالجتك بأدوية خفض ضغط الدم والتي تحتوي على أليسكيرين.</li></ul><p>إذا كنت غير متأكد من تطابق اي من الحالات اعلاه عليك، تحدث الى الطبيب أوالصيدلي قبل أخذ زينوبريل.</p><p>إذا تطورت عندك حالة من السعال الجاف واستمرت معك لفترة طويلة منذ بدء استعمالك لدواء زينوبريل، أخبر طبيبك بذلك.</p><p><strong>الإحتياطات عند استعمال زينوبريل</strong></p><p>تحدث الى طبيبك او الصيدلي قبل أخذ زينوبريل:</p><ul><li dir="rtl">&nbsp;إذا كانت لديك ضيق في الوتين (وهو شريان في القلب) أو ضيق بصمامات القلب (الصمامات التاجية).</li><li dir="rtl">&nbsp;إذا كانت لديك ضيق في الشريان الكلوي.</li><li dir="rtl">&nbsp;إذا كانت لديك زيادة في سماكة في عضلة القلب (المعروف باعتلال عضلة القلب التضخمي).</li><li dir="rtl">&nbsp;إذا كانت لديك مشاكل في الأوعية الدموية (داء وعائي كولاجيني).</li><li dir="rtl">&nbsp;إذا كانت لديك انخفاض في ضغط الدم. قد تلاحظ ذلك بشعورك بالدوار أو بالدوخة، خاصة عند وقوفك بعد الجلوس.</li><li dir="rtl">&nbsp;إذا كانت لديك مشاكل في الكلى أو كنت تقوم بغسيل الكلى.</li><li dir="rtl">&nbsp;إذا كانت لديك مشاكل في الكلى.</li><li dir="rtl">&nbsp;إذا كان لديك مرض السكري.</li><li dir="rtl">&nbsp;إذا كنت تأخذ أي من الأدوية التالية التي تستخدم لعلاج ارتفاع ضغط الدم:</li></ul><p>o مانع مستقبلات أنجيوتنسين الثاني (آربس) (المعروفه أيضا باسم سارتان - على سبيل المثال فالسارتان، - تلميسارتان، إربيسارتان)، ولا سيما إذا كان لديك مرض السكري مرتبط مع مشاكل في الكلى.</p><p>o أليسكيرين.</p><p>قد يتحقق طبيبك من وظيفة كليتيك وضغط دمك وكمية الأملاح التعويضية (مثل البوتاسيوم) في الدم على فترات منتظمة. انظر أيضا المعلومات تحت عنوان &quot;موانع استعمال زينوبريل&quot;.</p><ul><li dir="rtl">إذا كنت مؤخرا مصابا بالإسهال أو قيء.</li><li dir="rtl">إذا اخبرك الطبيب بضرورة التحكم بكميات الملح في نظامك الغذائي.</li><li dir="rtl">إذا كان لديك ارتفاع مستويات الكولسترول و تقوم بمعالجته بما يدعى ب &quot;فصادة البروتين الشحمي المنخفض الكثافة &quot;.</li><li dir="rtl">يجب اخبار الطبيب اذا كنتي تفكرين (أو ربما اصبحتي)&nbsp;حاملا. لاينصح بإستخدام زينوبريل في وقت الحمل المبكر، و يجب التوقف او عدم استعماله عند بلوغ ثلاثة اشهر من الحمل، كما قد يسبب ضرر خطير للطفل اذا استخدم في هذه المرحلة (انظر قسم الحمل والرضاعة).</li><li dir="rtl">إذا كنت ذو اصول سوداء زينوبريل قد يكون أقل فعالية. قد تكون معرض اكثر لحدوث العرض الجانبي الخطير &quot;الوذمة الوعائية&quot; (كرد فعل تحسسي خطير).</li></ul><p>إذا كنت غير متأكد من تطابق اي من الحالات اعلاه عليك، تحدث الى الطبيب أوالصيدلي قبل أخذ زينوبريل.</p><p><strong>علاج الحساسية كمعالجة لسعة الحشرات</strong><br />اخبر طبيبك اذا اخذت او في طريقك لأخذ علاج لتخفيض التأثير التحسسي كما يحدث في حال لسعة الحشرات (علاج تقليل الحساسية). لأنه اذا كنت تستعمل زينوبريل وانت تقوم بهذه المعالجة قد يسبب ذلك رد فعل تحسسي خطير.<br /><strong>العمليات</strong><br />إذا كنت ستقوم بإجراء عملية (بما في ذلك جراحة الأسنان) أخبر طبيبك او طبيب اسنانك بإستخدامك زينوبريل؛ وذلك لأنه قد تصاب بإنخفاض بضغط الدم اذا تم تخديرك تخديرا عاما او تخديرا موضعيا بسبب تناولك لزينوبريل.</p><p><strong>الأطفال والمراهقين</strong><br />لقد تمت دراسة زينوبريل على الأطفال، ولمزيد من المعلومات تحدث الى الطبيب. لاينصح بإستخدام زينوبريل للأطفال تحت ستة سنوات من العمر او لأي طفل يعاني من مشاكل كلوية حادة.<br /><strong>التداخلات الدوائية من أخذ زينوبريل مع أدوية اخرى او مكملات غذائية</strong><br />اخبر طبيبك اذا كنت تأخذ او اتخذت مؤخرا او كنت قد تستخدم اي من ألأدوية الأخرى وذلك بسبب ان زينوبريل قد يؤثر على طريقة عمل بعض الأدوية ومن جهة اخرى قد تؤثر الأدوية الأخرى على طريقة عمل زينوبريل. بسبب ذلك قد يحتاج طبيبك الى تغيير جرعة الدواء و/أو اتخاذ إحتياطات اخرى.<br />في على وجه الخصوص، اخبر الطبيب او الصيدلي إذا كنت تأخذ اي من الأدوية التالية:</p><ul><li>ادوية اخرى تساعد على خفض ضغط الدم.</li><li>مانع مستقبلات أنجيوتنسين الثاني (آربس) أو أليسيكرين (انظر ايضا الى المعلومات المدرجة تحت العنوان &quot;موانع استعمال زينوبريل&quot; و &quot; الإحتياطات عند استعمال زينوبريل&quot;).</li><li>&nbsp;أقراص الماء (الأدوية المدرة للبول).</li><li>&nbsp;الأدوية التي تقوم بتكسير جلطات الدم (عادة تعطى في المستشفى).</li><li>&nbsp;أدوية حاصرات بيتا، مثل أتينولول و بروبرانولول.</li><li>&nbsp;أدوية النترات (لعلاج مشاكل القلب).</li><li>&nbsp;المضادات الالتهابات غير الستيرويدية (المسكنات) تستعمل إلى علاج الألم و التهاب المفاصل.</li><li>&nbsp;الأسبرين ،إذا كنت تأخذ أكثر من ثلاثة غرام في اليوم الواحد.</li><li>&nbsp;الأدوية المعالجة للكآبة او المشاكل العقلية بما فيه الليثيوم.</li><li>&nbsp;أقراص البوتاسيوم او بدائل الملح التي تحتوي على البوتاسيوم ضمن تركيبها.</li><li>&nbsp;الأنسولين أو الأدوية التي تأخذ بواسطة الفم لعلاج مرض السكري.</li><li>&nbsp;الأدوية المستعملة لعلاج الربو.</li><li>&nbsp;الأدوية التي تعالج احتقان الأنف او الجيوب الأنفية أو ادوية علاج البرد الأخرى (تتضمن تلك التي تشترى من دون وصفة طبية)</li><li>&nbsp;الأدوية المثبطة لإستجابة الجسم المناعية .</li><li>الوبيورينول (لعلاج النقرس).</li><li>بروكاييناميد (لعلاج المشاكل في نبضات القلب).</li><li>&nbsp;الأدوية التي تحتوي على الذهب، مثل صوديوم أوروثيومالات، قد تعطى لك عن طريق الحقن.</li></ul><p><strong>الحمل والرضاعة<br />الحمل:</strong><br />يجب اخبار طبيبك اذا اعتقدت (أو ربما اصبحتي) حاملا ، من الطبيعي ان يخبرك الطبيب بوقف استعمال زينوبريل قبل ان تصبحي حاملا او في اقرب وقت تعلمين به انكك حامل وسوف يشير عليك بإستخدام دواء بديل لزينوبريل، لاينصح بإستخدام زينوبريل في وقت الحمل المبكر، و يجب&nbsp;التوقف او عدم استعماله عند بلوغ ثلاثة اشهر من الحمل، كما قد يسبب ضرر خطير للطفل اذا استخدم في هذه المرحلة.<br /><strong>الرضاعة الطبيعية:</strong><br />أخبري طبيبك اذا كنتي مرضعا او في طريقك للإرضاع، لاينصح بإستخدام زينوبريل للأمهات المرضعات، وسوف يختار لك طبيبك علاجا آخر اذا كنتي تودين الإرضاع خاصة اذا كان طفلك حديث الولادة او كان من الأطفال الخدج.<br /><strong>تأثير زينوبريل على القيادة و استخدام آلآلات</strong></p><ul><li>&nbsp;قد يشعر بعض الأشخاص بالدوار او التعب من جراء تناول هذا الدواء؛ اذا كان ذلك يحصل لك لاتقم بالقيادة او تشغيل او استعمال الآلات والأدوات.</li><li>&nbsp;يجب الإنتظار لمعرفة تأثير هذا الدواء عليك قبل القيام بأي من النشاطات أعلاه.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب استخدام هذا الدواء بالضبط كما أخبرك الطبيب، تأكد من طبيبك او الصيدلي اذا اردت التأكد من اي شئ..<br />بمجرد بدء استخدامك لزينوبريل سوف يأخذ منك الطبيب عينة لفحص الدم. ليقرر الطبيب بعدها ما إذا كانت جرعتك مناسبة لك او تحتاج<br />الى تعديل.<br /><strong>استخدام الدواء</strong></p><ul><li>ابتلع القرص مع شرب الماء.</li><li>حاول بتناول الأقراص في نفس التوقيت من كل يوم. من غير المهم تناول زينوبريل سواء كان قبل الأكل او بعده.</li><li>&nbsp;استمر بتناول زينوبريل طالما يخبرك طبيبك بذلك، يعتبر زينوبريل دواء طويل الأمد. انه من الضروري الحفاظ على تناول زينوبريل كل يوم.</li></ul><p><strong>تناول جرعتك الأولى</strong></p><ul><li dir="rtl">يجب الحيطة عندما تكون هذه جرعتك الأولى من زينوبريل او ان مقدار الجرعة قد ازداد. قد&nbsp;يسبب ذلك هبوط حاد في ضغط الدم مقارنة مع الجرعات المتتالية.</li><li>قد تشعر بالدوار او الدوخة . اذا حصل ذلك قد يساعدك الإستلقاء للتخلص منه، اذا أقلقك ذلك بإستطاعتك التحدث للطبيب في اقرب وقت.</li></ul><p><strong>الكبار</strong><br />تعتمد جرعتك على حالتك الصحية وماذا كنت تستخدم ادوية أخرى. سوف يخبرك الطبيب بعدد الأقراص التي يجب استعمالها يوميا.<br />تحقق من الطبيب او الصيدلي اذا لم تكن متأكدا من ذلك.<br /><strong>لإرتفاع ضغط الدم:</strong></p><ul><li>الجرعة الأولية الموصى بها هي 10&nbsp;ملجم مرة واحدة يوميا.</li><li>الجرعة الإعتيادية على المدى الطويل هي 20 ملجم مرة واحدة يوميا.</li></ul><p><strong>لفشل القلب:</strong></p><ul><li>&nbsp;الجرعة الأولية الموصى بها هي 2.5 ملجم مرة واحدة يوميا.</li><li>&nbsp;الجرعة الإعتيادية على المدى الطويل هي 5 الى 35 ملجم مرة واحدة يوميا.</li></ul><p><strong>بعد النوبة القلبية:</strong></p><ul><li dir="rtl">&nbsp;الجرعة الأولية الموصى بها هي 5 ملجم خلال 24 ساعة من اصابتك بالنوبة القلبية، يلي ذلك 5 ملجم مرة واحدة يوميا.</li><li dir="rtl">&nbsp;الجرعة الإعتيادية على المدى الطويل هي 10 ملجم مرة واحدة يوميا.</li></ul><p><strong>لمشاكل الكلى بسبب مرض السكري:</strong></p><ul><li dir="rtl">&nbsp;الجرعة الموصى بها اما 10ملجم او 20&nbsp;ملجم مرة واحدة يوميا.</li></ul><p>اذا كنت من كبار السن ولديك مشاكل في الكلى او كنت تستخدم الأدوية المدرة للبول قد يصف لك الطبيب جرعة أقل من الجرعة الإعتيادية.</p><p><strong>استعمال زينوبريل عند الأطفال و المراهقين (6 إلى 16سنوات العمر ) مع ارتفاع ضغط الدم</strong></p><ul><li dir="rtl">&nbsp;لايوصى باستعمال زينوبريل للأطفال تحت ستة سنوات من العمر او عند اي طفل يعاني مشاكل في الكلى.</li><li dir="rtl">سوف يقوم بإختيار الجرعة المناسبة لطفلك، تعتمد الجرعة الموصوفة على وزن جسم الطفل.</li><li dir="rtl">للأطفال الذين يزنون مابين 20 كيلوجرام و 50&nbsp;&nbsp;كيلوجرام جرعتهم الإبتدائية الموصى بها هي 2.5 ملجم مرة واحدة يوميا.</li><li dir="rtl">للأطفال لذين يزنون اكثر من 50&nbsp;ملجم، جرعتهم الإبتدائية الموصى بها هي 5 ملجم مرة واحدة يوميا.</li></ul><p><strong>الجرعة الزائدة من زينوبريل</strong><br />إذا اخذت زينوبريل أكثر من جرعتك الموصوفة من قبل الطبيب، تحدث الى الطبيب او اذهب الى المستشفى فورا. الأعراض التالية قد تكون أكثر ماقد يحدث: الدوخة والخفقان.<br /><strong>نسيان تناول جرعة زينوبريل</strong><br />اذا نسيت تناول جرعتك، تفضل بأخذها في اقرب وقت تتذكرها، على كل حال اذا تذكرت جرعتك المنسية في وقت قريب من الجرعة التالية تجاهل جرعتك المنسية وتناول جرعتك الحالية.<br /><strong>التوقف عن تناول زينوبريل</strong><br />لاتتوقف عن تناول أقراصك من تلقاء نفسك حتى وان شعرت بتحسن حالتك، ماعدا اذا اخبرك طبيبك بذلك. اذا احتجت لمعرفة المزيد عن طريقة استخدام الدواء، اسأل الطبيب او الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، هذا الدواء قد يسبب اعراضا جانبية، بالرغم من عدم حصولها لجميع المستخدمين.</p><p>إذا حصلت لك أحد الأعراض الجانبية التالية، <strong>توقف عن تناول زينوبريل و واذهب لرؤية طبيبك على الفور:</strong></p><ul><li>ردود فعل خطيرة للحساسية (نادرة، تؤثر على 1 مستخدم الى 10 مستخدمين من كل 10000&nbsp;مستخدم). الأعراض قد تشمل ظهور مفاجئ لمايلي:</li></ul><p>-تورم الوجه، الشفاه، اللسان أو الحلق. مما قد يصعب البلع.&nbsp;<br />-تورم حاد ومفاجئ في اليدين، القدم و الكاحلين.&nbsp;<br />-صعوبة التنفس.&nbsp;<br />-حكة شديدة في الجلد (مع ظهور نتوء).&nbsp;</p><ul><li>اضطراب حاد في الجلد، فجأة ظهور طفح جلدي او حروق غير متوقعة، احمرار او كشط للبشرة (نادر جدا، يؤثر&nbsp;على اقل من مستخدم واحد من 10000).</li><li>ظهور أعراض للعدوى كإرتفاع درجة الحرارة وتدهور خطير للحالة العامة او حدوث اعراض ارتفاع في درجة الحرارة مع عدوى محدودة مثل احتقان الحلق/ الحنجرة/ مشاكل بولية او بالفم. ((نادر جدا، يؤثر على اقل من&nbsp;مستخدم واحد من 10000).</li></ul><p><strong>الأعراض الجانبية الأخرى</strong><br /><strong>شائعة (يؤثر على 1 الى 10 مستخدمين من 100)</strong></p><ul><li>&nbsp;صداع.</li><li>&nbsp;الشعور بدوار أو بالدوخة، خاصة إذا وقفت بسرعة.</li><li>&nbsp;الإسهال.</li><li>&nbsp;سعال جاف لايتوقف.</li><li>&nbsp;التقيؤ.</li><li>مشاكل كلوية (كما يظهر في فحوصات الدم).</li></ul><p><strong>&nbsp;غير شائع (يؤثر على 1 إلى10&nbsp;مستخدمين من 1000)</strong></p><ul><li>&nbsp;تغييرات مزاجية.</li><li>&nbsp;تغيير في لون الأصابع لليدين او القدمين (اصفر باهت يليه احمرار) او تنميل او وخز بأصابع اليدين او القدمين.</li><li>&nbsp;تغيير في طريقة تذوق الأشياء.</li><li>&nbsp;شعور بالنعاس</li><li>&nbsp;شعور بالدوران (تأرحج)</li><li>&nbsp;صعوبات في النوم.</li><li>&nbsp;سكتة.</li><li>&nbsp;سرعة نبضات القلب</li><li>&nbsp;سيلان او رشح الأنف</li><li>&nbsp;الغثيان.</li><li>&nbsp;ألم في المعدة أو عسر الهضم.</li><li>&nbsp;طفح جلدي او حكة.</li><li>&nbsp;عدم القدرة على الانتصاب (عجز جنسي)</li><li>&nbsp;شعور بالتعب او بالضعف (فقدان القوة)</li><li>&nbsp;حدوث هبوط كبير في ضغط الدم قد يسبب الحالات التالية:امراض القلب التاجية، تضييق في الوتين (شريان القلب)،الشريان&nbsp;الكلوي او اوعية القلب، زيادة في سماكة عضلة القلب. اذا حصل لك ذلك قد تشعر بالدوخة او الدوار، خاصة عند وقوفك من وضعية الجلوس بسرعة.</li><li>&nbsp;تغييرات في نتائج فحوصات الدم لتظهر مدى فاعلية عمل الكلى والكبد.</li><li>&nbsp;نوبة قلبية</li><li>&nbsp;هلاوس بصرية و/أو سمعية.</li></ul><p><strong>&nbsp;نادر (يؤثر على 1 مستخدم إلى 10 مستخدمين من 10000)</strong></p><ul><li>&nbsp;الشعور بالاضطراب.</li><li>&nbsp;طفح مع وجود نتوءات.</li><li>&nbsp;جفاف الفم.</li><li>&nbsp;تساقط الشعر.</li><li>&nbsp;الصدفية (مرض جلدي).</li><li>&nbsp;تغيير في حاسة الشم.</li><li>&nbsp;وضوح الثديين عند الرجال.</li><li>&nbsp;تغييرات في بعض الخلايا و في اجزاء الدم. قد يأخذ منك الطبيب عينة من الدم لفحصها من وقت للآخر لمعرفة ما اذا كان لزينوبريل تأثير ام لا. وقد تكون علامات هذا التغيير هي الشعور بالتعب، بهتان البشرة، احتقان الحلق، ارتفاع درجة حرارة الجسم (حمى)، ألم بالعضلات والمفاصل، انتفاخ بالمفاصل او الغدد، او التحسس من أشعة الشمس.</li><li>&nbsp;انخفاض مستويات الصوديوم بالدم (و الأعراض قد تكون التعب، والصداع، و الغثيان و التقيؤ).</li><li>&nbsp;فشل كلوي مفاجئ.</li></ul><p><strong>&nbsp;نادر جدا (تؤثر في أقل من 1 مستخدم من 10000)</strong></p><ul><li>&nbsp;التهاب الجيوب الأنفية ( احساس بالألم والامتلاء خلف الوجنتين والعينين)</li><li>&nbsp;صفير عند التنفس.</li><li>انخفاض مستويات السكر في الدم (هايبوجلايسيميا). علامات ذلك قد تظهر بالجوع او التعب، التعرق وتسارع نبضات القلب.</li><li>&nbsp;التهاب الرئتين. وعلاماته: السعال، ضيق التنفس وارتفاع درجة حرارة الجسم (حمى).</li><li>&nbsp;اصفرار الجلد او اصفرار بياض العين (يرقان).</li><li>&nbsp;التهاب الكبد. قد يسبب ذلك فقدان الشهية، اصفرار الجلد والعينين، لون بول غامق.</li><li>&nbsp;التهاب البنكرياس. ويسبب ذلك الم من متوسط الى حاد للمعدة.</li><li>&nbsp;اضطراب حاد بالجلد. وتشمل الأعراض احمرار الجلد وتقرحه وتقشيره.</li><li>&nbsp;التعرق.</li><li>&nbsp;قلة التبول عن المعتاد او عدم التبول.</li><li>&nbsp;فشل كبدي.</li><li>&nbsp;نتوءات.</li><li>&nbsp;التهاب القناة الهضمية.</li></ul><p><strong>غير معروف (من غير الممكن معرفة ترددها من البيانات المتاحة)</strong></p><ul><li>&nbsp;أعراض الاكتئاب.</li><li>&nbsp;الإغماء.</li></ul><p><strong>الآثار الجانبية عند الأطفال مشابهة لها عند الكبار.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>حافظ على هذه الدواء بعيدا عن مرأى ومتناول الأطفال.</li><li>&nbsp;لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية ( EXP ) والذي جاء على الشريط الغلف للدواء والكرتون. تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر.</li><li>&nbsp;اقراص 5 ملجم و 10 ملجم و 20 ملجم: لا تخزن فوق 30 درجة مئوية.</li><li>&nbsp;لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيف تتخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ماهي محتويات زينوبريل</p><ul><li>المادة الفعالة هي: ليزينوبريل (كثنائي الهيدرات).</li><li>المواد المضافة الأخرى: السليلوز الجريزوفولفين. غليكولات نشا الصوديوم (برايموجل)؛ السيليكا الغروية اللامائية (ايريزول 200 )؛ ستيرات المغنيسيوم وأكسيد الحديد الأحمر(فقط في التركيبة التصنيعية لتركيزي 10 ملجم و 20 ملجم).</li><li>تتوفر اقراص الزينوبريل ثلالث تركيزات مختلفة وهي: 5 ملجم و 10&nbsp;ملجم أو 20 ملجم من ليزينوبريل (كثنائي الهيدرات).</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>أقراص زينوبريل 5 ملجم:</strong>أقراص دائرية محدبة الشكل بيضاء الى سكرية اللون، يقسم القرص خط طبع على النصف العلوي &ldquo;JI&rdquo;<br />وعلى النصف السفلي &ldquo;45&rdquo; .<br /><strong>أقراص زينوبريل 10 ملجم:</strong>أقراص دائرية الشكل وردية الى برتقالية اللون، يقسم القرص خط طبع على النصف العلوي &ldquo;JI&rdquo; وعلى<br />النصف السفلي &ldquo;42&rdquo; .<br /><strong>أقراص زينوبريل 20 ملجم:</strong>أقراص دائرية الشكل بلون القرميد الأحمر، يقسم القرص خط طبع على النصف العلوي &ldquo;JI&rdquo; وعلى النصف<br />السفلي &ldquo;43&rdquo;.</p><p>زينوبريل أقراص متوفرة داخل شرائط من الألومنيوم القصديري، وتحتوي العبوة على 28 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الجزيرة للصناعات الدوائية ( JPI )<br />الرياض، المملكة العربية السعودية، الرياض 11666 ، صندوق البريد 106229<br />رقم الهاتف:8172-207-11-966+<br />فاكس: 8097-207-11-966+<br />البريد الإلكتروني: <u>medical@jpi.com.sa</u></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2016، رقم النسخة 1.1
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zinopril 10 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains lisinopril dihydrate equivalent to 10 mg anhydrous lisinopril. 
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pinkish-orange scored round tablet embossed with "JI" on the top and "42"on the bottom.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Hypertension</strong></p><p>Treatment of hypertension.</p><p><strong>Heart failure</strong></p><p>Treatment of symptomatic heart failure.</p><p><strong>Acute myocardial infarction</strong></p><p>Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction.</p><p><strong>Renal complications of diabetes mellitus</strong></p><p>Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient nephropathy (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zinopril should be administered orally in a single daily dose. As with all other medication taken once daily, Zinopril should be taken at approximately the same time each day. The absorption of Zinopril tablets is not affected by food.</p><p>The dose should be individualised according to patient profile and blood pressure response (see section 4.4).</p><p><strong>Hypertension</strong></p><p>Zinopril may be used as monotherapy or in combination with other classes of antihypertensive therapy (see sections 4.3, 4.4, 4.5 and 5.1).</p><p><u>Starting dose</u></p><p>In patients with hypertension the usual recommended starting dose is 10 mg. Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and /or volume depletion, cardiac decompensation, or severe hypertension) may experience an excessive blood pressure fall following the initial dose. A starting dose of 2.5-5 mg is recommended in such patients and the initiation of treatment should take place under medical supervision. A lower starting dose is required in the presence of renal impairment (see Table 1 below).</p><p><u>Maintenance dose</u></p><p>The usual effective maintenance dosage is 20 mg administered in a single daily dose. In general, if the desired therapeutic effect cannot be achieved in a period of 2 to 4 weeks on a certain dose level, the dose can be further increased. The maximum dose used in long-term, controlled clinical trials was 80 mg/day.</p><p><u>Diuretic-treated patients</u></p><p>Symptomatic hypotension may occur following initiation of therapy with Zinopril. This is more likely in patients who are being treated currently with diuretics. Caution is recommended therefore, since these patients may be volume and/or salt depleted. If possible, the diuretic should be discontinued 2 to 3 days before beginning therapy with Zinopril. In hypertensive patients in whom the diuretic cannot be discontinued, therapy with Zinopril should be initiated with a 5 mg dose. Renal function and serum potassium should be monitored. The subsequent dosage of Zinopril should be adjusted according to blood pressure response. If required, diuretic therapy may be resumed (see section 4.4 and section 4.5).</p><p><u>Dosage adjustment in renal impairment</u></p><p>Dosage in patients with renal impairment should be based on creatinine clearance as outlined in Table 1 below.</p><p><strong>Table 1 Dosage adjustment in renal impairment</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine Clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Starting Dose (mg/day)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Less than 10 ml/min (including patients on dialysis)</p></td><td style="vertical-align:top"><p>2.5 mg*</p></td></tr><tr><td style="vertical-align:top"><p>10-30 ml/min</p></td><td style="vertical-align:top"><p>2.5-5 mg</p></td></tr><tr><td style="vertical-align:top"><p>31-80 ml/min</p></td><td style="vertical-align:top"><p>5-10 mg</p></td></tr></tbody></table><p>* Dosage and/or frequency of administration should be adjusted depending on the blood pressure response.</p><p>The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.</p><p><u>Use in hypertensive paediatric patients aged 6&ndash;16 years</u></p><p>The recommended initial dose is 2.5 mg once daily in patients 20 to &lt;50 kg, and 5 mg once daily in patients &ge;50 kg. The dosage should be individually adjusted to a maximum of 20 mg daily in patients weighing 20 to &lt;50 kg, and 40 mg in patients &ge;50 kg. Doses above 0.61 mg/kg (or in excess of 40 mg) have not been studied in paediatric patients (see section 5.1).</p><p>In children with decreased renal function, a lower starting dose or increased dosing interval should be considered.</p><p><strong>Heart failure</strong></p><p>In patients with symptomatic heart failure, Zinopril should be used as adjunctive therapy to diuretics and, where appropriate, digitalis or beta-blockers. Zinopril may be initiated at a starting dose of 2.5 mg once a day, which should be administered under medical supervision to determine the initial effect on the blood pressure. The dose of Zinopril should be increased:</p><ul><li>By increments of no greater than 10 mg</li><li>At intervals of no less than 2 weeks</li><li>To the highest dose tolerated by the patient up to a maximum of 35 mg once daily.</li></ul><p>Dose adjustment should be based on the clinical response of individual patients.</p><p>Patients at high risk of symptomatic hypotension, e.g. patients with salt depletion with or without hyponatraemia, patients with hypovolaemia or patients who have been receiving vigorous diuretic therapy should have these conditions corrected, if possible, prior to therapy with Zinopril. Renal function and serum potassium should be monitored (see section 4.4).</p><p><strong>Posology in Acute myocardial infarction</strong></p><p>Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin, and beta-blockers. Intravenous or transdermal glyceryl trinitrate may be used together with Zinopril.</p><p><u>Starting dose (first 3 days after infarction)</u></p><p>Treatment with Zinopril may be started within 24 hours of the onset of symptoms. Treatment should not be started if systolic blood pressure is lower than 100 mm Hg. The first dose of Zinopril is 5 mg given orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and then 10 mg once daily. Patients with a low systolic blood pressure (120 mm Hg or less) when treatment is started or during the first 3 days after the infarction should be given a lower dose - 2.5 mg orally (see section 4.4).</p><p>In cases of renal impairment (creatinine clearance &lt;80 ml/min), the initial Zinopril dosage should be adjusted according to the patient&#39;s creatinine clearance (see Table 1).</p><p><u>Maintenance dose</u></p><p>The maintenance dose is 10 mg once daily. If hypotension occurs (systolic blood pressure less than or equal to 100 mm Hg) a daily maintenance dose of 5 mg may be given with temporary reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure less than 90 mm Hg for more than 1 hour) Zinopril should be withdrawn.</p><p>Treatment should continue for 6 weeks and then the patient should be re-evaluated. Patients who develop symptoms of heart failure should continue with Zinopril (see section 4.2).</p><p><strong>Renal complications of diabetes mellitus</strong></p><p>In hypertensive patients with type 2 diabetes mellitus and incipient nephropathy, the dose is 10 mg Zinopril once daily which can be increased to 20 mg once daily, if necessary, to achieve a sitting diastolic blood pressure below 90 mm Hg.</p><p>In cases of renal impairment (creatinine clearance &lt;80 ml/min), the initial Zinopril dosage should be adjusted according to the patient&#39;s creatinine clearance (see Table 1).</p><p><strong>Paediatric population</strong></p><p>There is limited efficacy and safety experience in hypertensive children &gt;6 years old, but no experience in other indications (see section 5.1). Zinopril is not recommended in children in other indications than hypertension.</p><p>Zinopril is not recommended in children below the age of 6, or in children with severe renal impairment (GFR &lt; 30ml/min/1.73m<sup>2</sup>) (see section 5.2).</p><p><strong>Older people</strong></p><p>In clinical studies, there was no age-related change in the efficacy or safety profile of the drug. When advanced age is associated with decrease in renal function, however, the guidelines set out in Table 1 should be used to determine the starting dose of Zinopril. Thereafter, the dosage should be adjusted according to the blood pressure response.</p><p><strong>Use in kidney transplant patients</strong></p><p>There is no experience regarding the administration of Zinopril in patients with recent kidney transplantation. Treatment with Zinopril is therefore not recommended.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to Zinopril , to any of the excipients listed in section 6.1 or any other angiotensin converting enzyme (ACE) inhibitor
•	History of angioedema associated with previous ACE inhibitor therapy
•	Hereditary or idiopathic angioedema
•	Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
•	The concomitant use of Zinopril with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptomatic hypotension</strong></p><p>Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients. In hypertensive patients receiving Zinopril, hypotension is more likely to occur if the patient has been volume-depleted, e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting, or has severe renin-dependent hypertension (see section 4.5 and section 4.8). In patients with heart failure, with or without associated renal insufficiency, symptomatic hypotension has been observed. This is most likely to occur in those patients with more severe degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia or functional renal impairment. In patients at increased risk of symptomatic hypotension, initiation of therapy and dose adjustment should be closely monitored. Similar considerations apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.</p><p>If hypotension occurs, the patient should be placed in the supine position and, if necessary, should receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses, which can be given usually without difficulty once the blood pressure has increased after volume expansion.</p><p>In some patients with heart failure who have normal or low blood pressure, additional lowering of systemic blood pressure may occur with Zinopril. This effect is anticipated and is not usually a reason to discontinue treatment. If hypotension becomes symptomatic, a reduction of dose or discontinuation of Zinopril may be necessary.</p><p><strong>Hypotension in acute myocardial infarction</strong></p><p>Treatment with Zinopril must not be initiated in acute myocardial infarction patients who are at risk of further serious haemodynamic deterioration after treatment with a vasodilator. These are patients with systolic blood pressure of 100 mm Hg or lower, or those in cardiogenic shock. During the first 3 days following the infarction, the dose should be reduced if the systolic blood pressure is 120 mm Hg or lower. Maintenance doses should be reduced to 5 mg or temporarily to 2.5 mg if systolic blood pressure is 100 mm Hg or lower. If hypotension persists (systolic blood pressure less than 90 mm Hg for more than 1 hour) then Zinopril should be withdrawn.</p><p><strong>Aortic and mitral valve stenosis / hypertrophic cardiomyopathy</strong></p><p>As with other ACE inhibitors, Zinopril should be given with caution to patients with mitral valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or hypertrophic cardiomyopathy.</p><p><strong>Renal function impairment</strong></p><p>In cases of renal impairment (creatinine clearance &lt;80 ml/min), the initial Zinopril dosage should be adjusted according to the patient&#39;s creatinine clearance (see Table 1 in section 4.2), and then as a function of the patient&#39;s response to treatment. Routine monitoring of potassium and creatinine is part of normal medical practice for these patients.</p><p>In patients with <u>heart failure</u>, hypotension following the initiation of therapy with ACE inhibitors may lead to some further impairment in renal function. Acute renal failure, usually reversible, has been reported in this situation.</p><p>In some patients with <u>bilateral renal artery stenosis or with a stenosis of the artery to a solitary</u> <u>kidney</u>, who have been treated with angiotensin-converting enzyme inhibitors, increases in blood urea and serum creatinine, usually reversible upon discontinuation of therapy, have been seen. This is especially likely in patients with renal insufficiency. If renovascular hypertension is also present there is an increased risk of severe hypotension and renal insufficiency. In these patients, treatment should be started under close medical supervision with low doses and careful dose titration. Since treatment with diuretics may be a contributory factor to the above, they should be discontinued and renal function should be monitored during the first weeks of Zinopril therapy.</p><p>Some <u>hypertensive patients</u> with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when Zinopril has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or Zinopril may be required.</p><p>In <u>acute myocardial infarction</u>, treatment with Zinopril should not be initiated in patients with evidence of renal dysfunction, defined as serum creatinine concentration exceeding 177 micromol/l and/or proteinuria exceeding 500 mg/24 h. If renal dysfunction develops during treatment with Zinopril (serum creatinine concentration exceeding 265 micromol/l or a doubling from the pre-treatment value) then the physician should consider withdrawal of Zinopril.</p><p><strong>Hypersensitivity/Angioedema</strong></p><p>Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin-converting enzyme inhibitors, including Zinopril. This may occur at any time during therapy. In such cases, Zinopril should be discontinued promptly and appropriate treatment and monitoring should be instituted to ensure complete resolution of symptoms prior to dismissing the patients. Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient.</p><p>Very rarely, fatalities have been reported due to angioedema associated with laryngeal oedema or tongue oedema. Patients with involvement of the tongue, glottis or larynx, are likely to experience airway obstruction, especially those with a history of airway surgery. In such cases emergency therapy should be administered promptly. This may include the administration of adrenaline and/or the maintenance of a patent airway. The patient should be under close medical supervision until complete and sustained resolution of symptoms has occurred.</p><p>Angiotensin-converting enzyme inhibitors cause a higher rate of angioedema in black patients than in non-black patients.</p><p>Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see section 4.3).</p><p><strong>Anaphylactoid reactions in haemodialysis patients</strong></p><p>Anaphylactoid reactions have been reported in patients dialysed with high flux membranes (e.g. AN 69) and treated concomitantly with an ACE inhibitor. In these patients, consideration should be given to using a different type of dialysis membrane or different class of antihypertensive agent.</p><p><strong>Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis</strong></p><p>Rarely, patients receiving ACE inhibitors during low-density lipoproteins (LDL) apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.</p><p><strong>Desensitisation</strong></p><p>Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) have sustained anaphylactoid reactions. In the same patients, these reactions have been avoided when ACE inhibitors were temporarily withheld but they have reappeared upon inadvertent re-administration of the medicinal product.</p><p><strong>Hepatic failure</strong></p><p>Very rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving Zinopril who develop jaundice or marked elevations of hepatic enzymes should discontinue Zinopril and receive appropriate medical follow-up.</p><p><strong>Neutropenia/Agranulocytosis</strong></p><p>Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Neutropenia and agranulocytosis are reversible after discontinuation of the ACE inhibitor. Zinopril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections, which in a few instances did not respond to intensive antibiotic therapy. If Zinopril is used in such patients, periodic monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection.</p><p><strong>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</strong></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE- inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><strong>Race</strong></p><p>Angiotensin-converting enzyme inhibitors cause a higher rate of angioedema in black patients than in non-black patients.</p><p>As with other ACE inhibitors, Zinopril may be less effective in lowering blood pressure in black patients than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.</p><p><strong>Cough</strong></p><p>Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non- productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.</p><p><strong>Surgery/Anaesthesia</strong></p><p>In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, Zinopril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.</p><p><strong>Hyperkalaemia</strong></p><p>Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including Zinopril. Patients at risk for the development of hyperkalaemia include those with renal insufficiency, diabetes mellitus, or those using concomitant potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes, or those patients taking other drugs associated with increases in serum potassium (e.g. heparin). If concomitant use of the above-mentioned agents is deemed appropriate, regular monitoring of serum potassium is recommended (see section 4.5).</p><p><strong>Diabetic patients</strong></p><p>In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should be closely monitored during the first month of treatment with an ACE inhibitor (see 4.5 Interaction with other medicinal products and other forms of interaction).</p><p><strong>Lithium</strong></p><p>The combination of lithium and Zinopril is generally not recommended (see section 4.5).</p><p><strong>Pregnancy</strong></p><p>ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti- hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Antihypertensive agents</strong></p><p>When Zinopril is combined with other antihypertensive agents (e.g. glyceryl trinitrate and other nitrates, or other vasodilators), additive falls in blood pressure may occur.</p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><strong>Diuretics</strong></p><p>When a diuretic is added to the therapy of a patient receiving Zinopril the antihypertensive effect is usually additive.</p><p>Patients already on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure when Zinopril is added. The possibility of symptomatic hypotension with Zinopril can be minimised by discontinuing the diuretic prior to initiation of treatment with Zinopril (see section 4.4 and section 4.2).</p><p><strong>Potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes</strong></p><p>Although in clinical trials, serum potassium usually remained within normal limits, hyperkalaemia did occur in some patients. Risk factors for the development of hyperkalaemia include renal insufficiency, diabetes mellitus, and concomitant use of potassium-sparing diuretics (e.g. spironolactone, triamterene or amiloride), potassium supplements or potassium- containing salt substitutes. The use of potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes, particularly in patients with impaired renal function, may lead to a significant increase in serum potassium. If Zinopril is given with a potassium-losing diuretic, diuretic-induced hypokalaemia may be ameliorated.</p><p><strong>Lithium</strong></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide diuretics may increase the risk of lithium toxicity and enhance the already increased lithium toxicity with ACE inhibitors. Use of Zinopril with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see section 4.4).</p><p><strong>Non-steroidal anti-inflammatory medicinal products (NSAIDs) including acetylsalicylic acid &ge; 3 g/day</strong></p><p>When ACE-inhibitors are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non- selective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACE-inhibitors and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. These effects are usually reversible. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p><strong>Gold</strong></p><p>Nitritoid reactions (symptoms of vasodilatation including flushing, nausea, dizziness and hypotension, which can be very severe) following injectable gold (for example, sodium aurothiomalate) have been reported more frequently in patients receiving ACE inhibitor therapy.</p><p><strong>Tricyclic antidepressants / Antipsychotics / Anaesthetics</strong></p><p>Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see section 4.4).</p><p><strong>Sympathomimetics</strong></p><p>Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.</p><p><strong>Antidiabetics</strong></p><p>Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood glucose-lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.</p><p><strong>Tissue Plasminogen Activators</strong></p><p>Concomitant treatment with tissue plasminogen activators may increase the risk of angioedema.</p><p><strong>Acetylsalicylic acid, thrombolytics, beta-blockers, nitrates</strong></p><p>Zinopril may be used concomitantly with acetylsalicylic acid (at cardiologic doses), thrombolytics, beta-blockers and/or nitrates.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see section 4.4).</p><p>The use of ACE inhibitors is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p></td></tr></tbody></table><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitors therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).</p><p>Should exposure to ACE inhibitors have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p><strong>Breastfeeding</strong></p><p>Because no information is available regarding the use of Zinopril during breast-feeding, Zinopril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When driving vehicles or operating machines it should be taken into account that occasionally dizziness or tiredness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following undesirable effects have been observed and reported during treatment with Zinopril and other ACE inhibitors with the following frequencies: Very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p><strong>Blood and the lymphatic system disorders</strong></p></td></tr><tr><td><p>rare:</p></td><td><p>decreases in haemoglobin, decreases in haematocrit</p></td></tr><tr><td><p>very rare:</p></td><td><p>bone marrow depression, anaemia, thrombocytopenia, leucopenia,</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>neutropenia, agranulocytosis (see section 4.4), haemolytic anaemia,</p><p>lymphadenopathy, autoimmune disease.</p></td></tr><tr><td colspan="2"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td><p>very rare:</p></td><td><p>hypoglycaemia.</p></td></tr><tr><td colspan="2"><p><strong>Nervous system and psychiatric disorders</strong></p></td></tr><tr><td><p>common:</p></td><td><p>dizziness, headache</p></td></tr><tr><td><p>uncommon:</p></td><td><p>mood alterations, paraesthesia, vertigo, taste disturbance, sleep disturbances, hallucinations.</p></td></tr><tr><td><p>rare:</p></td><td><p>mental confusion, olfactory disturbance frequency</p></td></tr><tr><td><p>not known:</p></td><td><p>depressive symptoms, syncope.</p></td></tr><tr><td colspan="2"><p><strong>Cardiac and vascular disorders</strong></p></td></tr><tr><td><p>common:</p></td><td><p>orthostatic effects (including hypotension)</p></td></tr><tr><td><p>uncommon:</p></td><td><p>myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see section 4.4), palpitations, tachycardia, Raynaud&#39;s phenomenon.</p></td></tr><tr><td colspan="2"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p>common:</p></td><td><p>cough</p></td></tr><tr><td><p>uncommon:</p></td><td><p>rhinitis</p></td></tr><tr><td><p>very rare:</p></td><td><p>bronchospasm, sinusitis, allergic alveolitis/eosinophilic pneumonia.</p></td></tr><tr><td colspan="2"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td><p>common:</p></td><td><p>diarrhoea, vomiting</p></td></tr><tr><td><p>uncommon:</p></td><td><p>nausea, abdominal pain and indigestion</p></td></tr><tr><td><p>rare:</p></td><td><p>dry mouth</p></td></tr><tr><td><p>very rare:</p></td><td><p>pancreatitis, intestinal angioedema, hepatitis - either hepatocellular or cholestatic, jaundice and hepatic failure (see section 4.4).</p></td></tr><tr><td colspan="2"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td><p>uncommon:</p></td><td><p>rash, pruritus</p></td></tr><tr><td><p>rare:</p></td><td><p>urticaria, alopecia, psoriasis, hypersensitivity/angioneurotic oedema: angioneurotic oedema of the face, extremities, lips, tongue, glottis, and/or larynx (see section 4.4)</p></td></tr><tr><td><p>very rare:</p></td><td><p>sweating, pemphigus, toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, cutaneous pseudolymphoma.</p></td></tr></tbody></table><p>A symptom complex has been reported which may include one or more of the following: fever, vasculitis, myalgia, arthralgia/arthritis, positive antinuclear antibodies (ANA), elevated red blood cell sedimentation rate (ESR), eosinophilia and leucocytosis, rash, photosensitivity or other dermatological manifestations may occur.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td><p>common:</p></td><td><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; renal dysfunction</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>rare:</p></td><td><p>uraemia, acute renal failure</p></td></tr><tr><td><p>very rare:</p></td><td><p>oliguria/anuria.</p></td></tr><tr><td><p><strong>Endocrine disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>rare:</p></td><td><p>syndrome of inappropriate antidiuretic hormone secretion (SIADH).</p></td></tr><tr><td colspan="2"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td><p>uncommon:</p></td><td><p>impotence</p></td></tr><tr><td><p>rare:</p></td><td><p>gynaecomastia.</p></td></tr><tr><td colspan="2"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td><p>uncommon:</p></td><td><p>fatigue, asthenia.</p></td></tr><tr><td><p><strong>Investigations</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>uncommon:</p></td><td><p>increases in blood urea, increases in serum creatinine, increases in liver enzymes, hyperkalaemia</p></td></tr><tr><td><p>rare:</p></td><td><p>increases in serum bilirubin, hyponatraemia.</p></td></tr></tbody></table><p>Safety data from clinical studies suggest that lisinopril is generally well tolerated in hypertensive paediatric patients, and that the safety profile in this age group is comparable to that seen in adults.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting systems applied at their countries.</p><ul><li>&nbsp;Saudi Arabia:</li></ul><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>Website: <u>www.sfda.gov.sa/npc</u></p><p>Other GCC States: Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data are available for overdose in humans. Symptoms associated with overdosage of ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough. The recommended treatment of overdose is intravenous infusion of normal saline solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. If ingestion is recent, take measures aimed at eliminating Zinopril (e.g. emesis, gastric lavage, administration of absorbents and sodium sulphate). Zinopril may be removed from the general circulation by haemodialysis (see section 4.4). Pacemaker therapy is indicated for therapy- resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored frequently.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin-converting enzyme inhibitors, ATC code: C09A A03.</p><p><u>Mechanism of Action</u></p><p>Zinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin-converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion. The latter decrease may result in an increase in serum potassium concentration.</p><p><u>Pharmacodynamic effects</u></p><p>Whilst the mechanism through which lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in patients with low renin hypertension. ACE is identical to kininase II, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodilatory peptide, play a role in the therapeutic effects of lisinopril remains to be elucidated.</p><p><u>Clinical efficacy and safety</u></p><p>The effect of Zinopril on mortality and morbidity in heart failure has been studied by comparing a high dose (32.5 mg or 35 mg once daily) with a low dose (2.5 mg or 5 mg once daily). In a study of 3164 patients, with a median follow-up period of 46 months for surviving patients, high dose Zinopril produced a 12% risk reduction in the combined endpoint of all-cause mortality and all-cause hospitalisation (p = 0.002) and an 8% risk reduction in all-cause mortality and cardiovascular hospitalisation (p = 0.036) compared with low dose. Risk reductions for all-cause mortality (8%; p = 0.128) and cardiovascular mortality (10%; p = 0.073) were observed. In a post-hoc analysis, the number of hospitalisations for heart failure was reduced by 24% (p=0.002) in patients treated with high-dose Zinopril compared with low dose. Symptomatic benefits were similar in patients treated with high and low doses of Zinopril.</p><p>The results of the study showed that the overall adverse event profiles for patients treated with high or low dose Zinopril were similar in both nature and number. Predictable events resulting from ACE inhibition, such as hypotension or altered renal function, were manageable and rarely led to treatment withdrawal. Cough was less frequent in patients treated with high dose Zinopril compared with low dose.</p><p>In the GISSI-3 trial, which used a 2x2 factorial design to compare the effects of Zinopril and glyceryl trinitrate given alone or in combination for 6 weeks versus control in 19,394 patients</p><p>who were administered the treatment within 24 hours of an acute myocardial infarction, Zinopril produced a statistically significant risk reduction in mortality of 11% versus control (2p=0.03). The risk reduction with glyceryl trinitrate was not significant but the combination of Zinopril and glyceryl trinitrate produced a significant risk reduction in mortality of 17% versus control (2p=0.02). In the sub-groups of elderly (age &gt; 70 years) and females, pre-defined as patients at high risk of mortality, significant benefit was observed for a combined endpoint of mortality and cardiac function. The combined endpoint for all patients, as well as the high-risk sub-groups at 6 months, also showed significant benefit for those treated with Zinopril or Zinopril plus glyceryl trinitrate for 6 weeks, indicating a prevention effect for Zinopril. As would be expected from any vasodilator treatment, increased incidences of hypotension and renal dysfunction were associated with Zinopril treatment but these were not associated with a proportional increase in mortality.</p><p>In a double-blind, randomised, multicentre trial which compared Zinopril with a calcium channel blocker in 335 hypertensive Type 2 diabetes mellitus subjects with incipient nephropathy characterised by microalbuminuria, Zinopril 10 mg to 20 mg administered once daily for 12 months, reduced systolic/diastolic blood pressure by 13/10 mmHg and urinary albumin excretion rate by 40%. When compared with the calcium channel blocker, which produced a similar reduction in blood pressure, those treated with Zinopril showed a significantly greater reduction in urinary albumin excretion rate, providing evidence that the ACE inhibitory action of Zinopril reduced microalbuminuria by a direct mechanism on renal tissues in addition to its blood pressure-lowering effect.</p><p>Lisinopril treatment does not affect glycaemic control as shown by a lack of significant effect on levels of glycated haemoglobin (HbA1c).</p><p><em>Renin-angiotensin system (RAS)-acting agents</em></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p><u>Paediatric population</u></p><p>In a clinical study involving 115 paediatric patients with hypertension, aged 6&ndash;16 years, patients who weighed less than 50 kg received either 0.625 mg, 2.5 mg or 20 mg of Zinopril once a day, and patients who weighed 50 kg or more received either 1.25 mg, 5 mg or 40 mg of Zinopril once a day. At the end of 2 weeks, Zinopril administered once daily lowered trough blood pressure in a dose-dependent manner with a consistent antihypertensive efficacy demonstrated at doses greater than 1.25 mg.</p><p>This effect was confirmed in a withdrawal phase, where the diastolic pressure rose by about 9 mm Hg more in patients randomised to placebo than it did in patients who were randomised to remain on the middle and high doses of Zinopril. The dose-dependent antihypertensive effect of Zinopril was consistent across several demographic subgroups: age, Tanner stage, gender, and race.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lisinopril is an orally active non-sulphydryl-containing ACE inhibitor.</p><p><strong>Absorption</strong></p><p>Following oral administration of lisinopril, peak serum concentrations occur within about 7 hours, although there was a trend to a small delay in time taken to reach peak serum concentrations in acute myocardial infarction patients. Based on urinary recovery, the mean extent of absorption of lisinopril is approximately 25% with interpatient variability of 6-60% over the dose range studied (5-80 mg). The absolute bioavailability is reduced approximately 16% in patients with heart failure. Lisinopril absorption is not affected by the presence of food.</p><p><strong>Distribution</strong></p><p>Lisinopril does not appear to be bound to serum proteins other than to circulating angiotensin- converting enzyme (ACE). Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly.</p><p><strong>Elimination</strong></p><p>Lisinopril does not undergo metabolism and is excreted entirely unchanged into the urine. On multiple dosing, lisinopril has an effective half-life of accumulation of 12.6 hours. The clearance of lisinopril in healthy subjects is approximately 50 ml/min. Declining serum concentrations exhibit a prolonged terminal phase, which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose.</p><p><strong>Hepatic impairment</strong></p><p>Impairment of hepatic function in cirrhotic patients resulted in a decrease in lisinopril absorption (about 30% as determined by urinary recovery), but an increase in exposure (approximately 50%) compared to healthy subjects due to decreased clearance.</p><p><strong>Renal impairment</strong></p><p>Impaired renal function decreases elimination of lisinopril, which is excreted via the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below 30 ml/min. In mild to moderate renal impairment (creatinine clearance 30-80 ml/min), mean AUC was increased by 13% only, while a 4.5- fold increase in mean AUC was observed in severe renal impairment (creatinine clearance 5-30 ml/min).</p><p>Lisinopril can be removed by dialysis. During 4 hours of haemodialysis, plasma lisinopril concentrations decreased on average by 60%, with a dialysis clearance between 40 and 55 ml/min.</p><p><strong>Heart failure</strong></p><p>Patients with heart failure have a greater exposure of lisinopril when compared to healthy subjects (an increase in AUC on average of 125%), but based on the urinary recovery of lisinopril, there is reduced absorption of approximately 16% compared to healthy subjects.</p><p><strong>Paediatric population</strong></p><p>The pharmacokinetic profile of lisinopril was studied in 29 paediatric hypertensive patients, aged between 6 and 16 years, with a GFR above 30 ml/min/1.73m<sup>2</sup>. After doses of 0.1 to 0.2 mg/kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours, and the extent of absorption based on urinary recovery was about 28%. These values are similar to those obtained previously in adults.</p><p>AUC and C<sub>max</sub> values in children in this study were consistent with those observed in adults.</p><p><strong>Older people</strong></p><p>Older patients have higher blood levels and higher values for the area under the plasma concentration-time curve (increased approximately 60%) compared with younger subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of general pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. Angiotensin- converting enzyme inhibitors, as a class, have been shown to induce adverse effects on the late foetal development, resulting in foetal death and congenital effects, in particular affecting the skull. Foetotoxicity, intrauterine growth retardation and patent ductus arteriosus have also been reported. These developmental anomalies are thought to be partly due to a direct action of ACE inhibitors on the foetal renin-angiotensin system and partly due to ischaemia resulting from maternal hypotension and decreases in foetal-placental blood flow and oxygen/nutrients delivery to the foetus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Microcrystalline Cellulose<br />- Sodium Starch Glycolate (Primojel)<br />- Red iron oxide<br />- Colloidal Anhydrous Silica (Aerosil 200)<br />- Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PVDC clear &amp; Aluminum foil.<br />Not all pack sizes may be marketed.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries (JPI)
Riyadh, Saudi Arabia
11666 Riyadh, P.O.Box 106229

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11 May 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>